Letrozol Loxoprel

Letrozole, the active ingredient in Letrozol Loxoprel, is an aromatase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of estrogen receptor‑positive breast cancer in postmenopausal women. GNH USA supplies Letrozol Loxoprel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Letrozol Loxoprel is an aromatase inhibitor used in hormone‑dependent breast cancer therapy. - Early‑stage estrogen receptor‑positive breast cancer: reduces recurrence after surgery. - Metastatic estrogen receptor‑positive breast cancer: slows disease progression. - Adjuvant therapy for postmenopausal women: improves disease‑free survival.

Letrozol Loxoprel may cause a range of adverse reactions.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Arthralgia: joint pain or stiffness. - Fatigue: persistent tiredness not relieved by rest. - Nausea: mild to moderate upset stomach.

Serious or Rare Side Effects: - Severe liver injury: jaundice, dark urine, elevated enzymes. - Bone fracture: increased risk due to reduced bone density. - Pulmonary embolism: sudden shortness of breath, chest pain. - Allergic reaction: rash, swelling, difficulty breathing.

Before initiating Letrozol Loxoprel, clinicians should consider several safety measures. - Bone health monitoring: assess baseline bone mineral density and consider calcium/vitamin D supplementation. - Liver function assessment: obtain baseline hepatic enzymes and monitor periodically. - Cardiovascular risk evaluation: review history of thromboembolic events. - Pregnancy avoidance: contraindicated in pregnant or nursing women; ensure effective contraception. - Drug interaction vigilance: avoid concurrent use with strong CYP3A4 inducers or inhibitors without dose adjustment. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Letrozol Loxoprel can interact with several medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Tamoxifen: antagonistic effect reduces therapeutic benefit. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly lower plasma levels. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase exposure and toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of anticoagulant effect, monitor INR. - SSRIs (e.g., fluoxetine): may affect hormone metabolism, observe for side‑effects. - NSAIDs: increased risk of gastrointestinal irritation, advise caution.